References
- 1
Bader W, Melchner D, Nonenmacher T, Haen E.
Determination of five commonly used antipsychotics in human serum by high-performance
liquid chromatography (HPLC) and electrochemical detection.
Pharmacopsychiatry.
2005;
38
42
- 2
Baumann P, Hiemke C, Ulrich S. et al .
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry.
2004;
37
243-265
- 3
Greiner C, Haen E.
Therapeutic drug monitoring in psychiatry - reference ranges for the dose-concentration
relationship.
Psychiatrische Praxis.
2007;
34
90-92
- 4
Haen E.
Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen
zur Therapieleitung.
Psychopharmakotherapie.
2005;
12
138-143
- 5
Haen E, Greiner C, Bader W, Wittmann M.
Wirkstoffkonzentrationsbestimmungen zur Therapieleitung - Ergänzung therapeutischer
Referenzbereiche durch dosisbezogene Referenzbereiche, submitted to “Der Nervenarzt”.
.
- 6
Scordo MG, Spina E, Facciola G. et al .
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Psychopharmacology.
1999;
147
300-305
- 7
Snoeck E, Peer A van, Sack M. et al .
Influence of age, renal and liver impairment on the pharmacokinetics of risperidone
in man.
Psychopharmacology.
1995;
122
223-229
Correspondence
W. Bader
Clinical Pharmacology, Department of Psychiatry, Psychosomatics and Psychotherapy
University of Regensburg
Universitätsstraße 84
93053 Regensburg
Germany
Phone: +49/941/941 20 83
Fax: +49/941/941 20 65
Email: wolfgang.bader@klinik.uni-regensburg.de
